After seeing so many biotech share prices jump or plummet based on drug trials well before the drug is even approved, it is refreshing to discuss a company like Regeneron (NASDAQ:REGN). Regeneron's Eylea is experiencing incredible growth worldwide as a treatment for wet age-related macular degeneration, and the company is enjoying soaring profitability as a result. The stock is far from cheap, priced at 35 times forward earnings estimates, but Eylea has just gotten final approval from the European Commission for its macular degeneration indication in Europe, which means yet another market to add to the drug's dizzying growth story and more upward expansion from here.
Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.